Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-10-25
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of ipilimumab
and stereotactic body radiation therapy (SBRT). The safety and effectiveness of these
treatments given consecutively will also be studied.
This is an investigational study. SBRT is FDA approved for the control of metastatic and
primary tumors. Ipilimumab is FDA approved and commercially available for the treatment of
metastatic melanoma that cannot be removed with surgery. The use of SBRT with ipilimumab is
investigational. The study doctor can explain how the study drug is designed to work.
Up to 120 participants will be enrolled in this study. All will take part at MD Anderson.